farampator farampator farampator (developmental code names cx-691, org-24448, sch-900460) is an ampakine drug. it was developed by cortex pharmaceuticals, and licensed to organon biosciences for commercial development. following the purchase of organon by schering-plough in 2007, the development license to farampator was transferred. the development of farampator was eventually terminated, reportedly due to concerns about cardiac toxicity. farampatorclinical dataother namescx-691; org-24448legal statuslegal status us: investigational new drug identifiers iupac name 2,1,3-benzoxadiazol-6-yl-piperidin-1-ylmethanone cas number211735-76-1 ypubchem cid4118151chemspider3331565 nunii7x6p5n8k2lkeggd04131 ycomptox dashboard (epa)dtxsid90175413 chemical and physical dataformulac12h13n3o2molar mass231.255 g·mol−13d model (jsmol)interactive image smiles c1ccn(cc1)c(=o)c2=cc3=non=c3c=c2 inchi inchi=1s/c12h13n3o2/c16-12(15-6-2-1-3-7-15)9-4-5-10-11(8-9)14-17-13-10/h4-5,8h,1-3,6-7h2 nkey:xfvrbykkggdpaj-uhfffaoysa-n n ny (what is this?) (verify) farampator has been investigated for its effect on ampa receptors and researched for potential use in the treatment of schizophrenia and alzheimer's disease. it was found to improve short-term memory, but impaired episodic memory. it produced side effects such as headache, somnolence and nausea. subjects reporting side effects had significantly higher plasma levels of farampator than subjects without. additional analyses revealed that in the farampator condition the group without side effects showed a significantly superior memory performance relative to the group with side effects.